QUEST PHARMATECH INC (QPT.CA) Stock Price, Forecast & Analysis
Canada - TSX Venture Exchange - TSX-V:QPT - CA74836M1068 - Common Stock
QPT.CA Key Statistics, Chart & Performance
The current stock price of QPT.CA is 0.035 CAD. In the past month the price decreased by -22.22%. In the past year, price increased by 40%.
QPT.CA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| EPRX.CA | EUPRAXIA PHARMACEUTICALS INC | N/A | 538.41M | ||
| EDT.CA | SPECTRAL MEDICAL INC | N/A | 375.91M | ||
| HBP.CA | HELIX BIOPHARMA CORP | N/A | 183.31M | ||
| MDNA.CA | MEDICENNA THERAPEUTICS CORP | N/A | 78.41M | ||
| COV.CA | COVALON TECHNOLOGIES LTD | 24.14 | 46.68M | ||
| MBX.CA | MICROBIX BIOSYSTEMS INC | N/A | 32.66M | ||
| RVX.CA | RESVERLOGIX CORP | N/A | 27.30M | ||
| BCT.CA | BRIACELL THERAPEUTICS CORP | N/A | 18.22M | ||
| HEM.CA | HEMOSTEMIX INC | N/A | 16.02M | ||
| MPH.CA | MEDICURE INC | N/A | 13.05M | ||
| CSCI.CA | COSCIENS BIOPHARMA INC | N/A | 9.06M | ||
| KNE.CA | KANE BIOTECH INC | N/A | 6.69M |
Related stock screener links
About QPT.CA
Company Profile
Quest PharmaTech, Inc. is a biotechnology company, which develops and commercializes antibody based immunotherapeutic products for cancer. The company is headquartered in Edmonton, Alberta. The firm is developing products to improve the quality of life. The firm is also developing a proprietary MAb AR 9.6 targeting truncated MUC16 as theranostic agents for cancer. The firm has a 42.5% ownership interest in OncoQuest Inc. (OncoQuest), a Canadian biotechnology company developing combinatorial immunotherapy products for the treatment of cancer. OncoQuest’s technology platform included a panel of tumor antigen-specific monoclonal antibodies of the immunoglobulin G (IgG) and E (IgE) class targeting CA125, MUC1, PSA, Her2/neu, CA 19.9 and TAG72; and the application of combinatorial immunotherapy to enhance tumor specific immunity and clinical outcome. The firm also has a 23% ownership interest in OncoVent Co., Ltd. (OncoVent), which is developing antibody-based immunotherapeutic products for cancer for the Greater China territory.
Company Info
QUEST PHARMATECH INC
4342 97 Street
Edmonton ALBERTA T6E 6S4 CA
CEO: Ragupathy Madiyalakan,
Employees: 0
Phone: 17804481400
QUEST PHARMATECH INC / QPT.CA FAQ
What does QUEST PHARMATECH INC do?
Quest PharmaTech, Inc. is a biotechnology company, which develops and commercializes antibody based immunotherapeutic products for cancer. The company is headquartered in Edmonton, Alberta. The firm is developing products to improve the quality of life. The firm is also developing a proprietary MAb AR 9.6 targeting truncated MUC16 as theranostic agents for cancer. The firm has a 42.5% ownership interest in OncoQuest Inc. (OncoQuest), a Canadian biotechnology company developing combinatorial immunotherapy products for the treatment of cancer. OncoQuest’s technology platform included a panel of tumor antigen-specific monoclonal antibodies of the immunoglobulin G (IgG) and E (IgE) class targeting CA125, MUC1, PSA, Her2/neu, CA 19.9 and TAG72; and the application of combinatorial immunotherapy to enhance tumor specific immunity and clinical outcome. The firm also has a 23% ownership interest in OncoVent Co., Ltd. (OncoVent), which is developing antibody-based immunotherapeutic products for cancer for the Greater China territory.
What is the current price of QPT stock?
The current stock price of QPT.CA is 0.035 CAD. The price decreased by -12.5% in the last trading session.
Does QUEST PHARMATECH INC pay dividends?
QPT.CA does not pay a dividend.
What is the ChartMill technical and fundamental rating of QPT stock?
QPT.CA has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Should I buy QPT stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on QPT.CA.
Can you provide the upcoming earnings date for QUEST PHARMATECH INC?
QUEST PHARMATECH INC (QPT.CA) will report earnings on 2026-05-26.
QPT.CA Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to QPT.CA. When comparing the yearly performance of all stocks, QPT.CA is one of the better performing stocks in the market, outperforming 71.1% of all stocks.
QPT.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to QPT.CA. QPT.CA has a bad profitability rating. Also its financial health evaluation is rather negative.
QPT.CA Financial Highlights
Over the last trailing twelve months QPT.CA reported a non-GAAP Earnings per Share(EPS) of -0.01. The EPS decreased by -108.34% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -4.94% | ||
| ROE | -5.2% | ||
| Debt/Equity | 0.05 |